Within-Host and Between-Host Evolution in SARS-CoV-2—New Variant’s Source

Some of the newly emerging corona viral variants show high numbers of mutations. This is unexpected for a virus with a low mutation rate due to an inherent proof-reading system. Could such a variant arise under very special conditions occurring in a host where the virus replicates and mutates in a r...

Full description

Bibliographic Details
Main Author: Karin Moelling
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Viruses
Subjects:
Online Access:https://www.mdpi.com/1999-4915/13/5/751
id doaj-dce4ef5ef3e84ad0aa3d36193549fc57
record_format Article
spelling doaj-dce4ef5ef3e84ad0aa3d36193549fc572021-04-25T23:00:57ZengMDPI AGViruses1999-49152021-04-011375175110.3390/v13050751Within-Host and Between-Host Evolution in SARS-CoV-2—New Variant’s SourceKarin Moelling0Institute Medical Microbiology, University Zurich, Gloriastr 30, 8006 Zurich, SwitzerlandSome of the newly emerging corona viral variants show high numbers of mutations. This is unexpected for a virus with a low mutation rate due to an inherent proof-reading system. Could such a variant arise under very special conditions occurring in a host where the virus replicates and mutates in a rather unlimited fashion, such as in immune compromised patients? The virus was shown to replicate in an immunosuppressed cancer patient for more than 105 days and might be a source of new variants. These patients are asymptomatic and the virus may therefore escape detection and attention and be high-risk. Similarly, HIV-infected individuals may be immunocompromised and support coronavirus replication with increased mutation rates. The patients may promote “within-host evolution”. Some of the viruses present in such a highly mutagenic swarm or quasispecies within one patient may become founders and cause a pandemic by further “between-host evolution”. B.1.1.7 with 23 mutations may be such a case. Immunosuppressed patients can be identified and treated by the synthetic antibody cocktails as passive immunization and kept under control. Immunosuppressed patients can be easily identified and supervised by healthcare workers—once they become aware of the risk—to avoid new variants with pandemic potential.https://www.mdpi.com/1999-4915/13/5/751coronapandemicimmunosuppressionemerging variantsriskorigin
collection DOAJ
language English
format Article
sources DOAJ
author Karin Moelling
spellingShingle Karin Moelling
Within-Host and Between-Host Evolution in SARS-CoV-2—New Variant’s Source
Viruses
corona
pandemic
immunosuppression
emerging variants
risk
origin
author_facet Karin Moelling
author_sort Karin Moelling
title Within-Host and Between-Host Evolution in SARS-CoV-2—New Variant’s Source
title_short Within-Host and Between-Host Evolution in SARS-CoV-2—New Variant’s Source
title_full Within-Host and Between-Host Evolution in SARS-CoV-2—New Variant’s Source
title_fullStr Within-Host and Between-Host Evolution in SARS-CoV-2—New Variant’s Source
title_full_unstemmed Within-Host and Between-Host Evolution in SARS-CoV-2—New Variant’s Source
title_sort within-host and between-host evolution in sars-cov-2—new variant’s source
publisher MDPI AG
series Viruses
issn 1999-4915
publishDate 2021-04-01
description Some of the newly emerging corona viral variants show high numbers of mutations. This is unexpected for a virus with a low mutation rate due to an inherent proof-reading system. Could such a variant arise under very special conditions occurring in a host where the virus replicates and mutates in a rather unlimited fashion, such as in immune compromised patients? The virus was shown to replicate in an immunosuppressed cancer patient for more than 105 days and might be a source of new variants. These patients are asymptomatic and the virus may therefore escape detection and attention and be high-risk. Similarly, HIV-infected individuals may be immunocompromised and support coronavirus replication with increased mutation rates. The patients may promote “within-host evolution”. Some of the viruses present in such a highly mutagenic swarm or quasispecies within one patient may become founders and cause a pandemic by further “between-host evolution”. B.1.1.7 with 23 mutations may be such a case. Immunosuppressed patients can be identified and treated by the synthetic antibody cocktails as passive immunization and kept under control. Immunosuppressed patients can be easily identified and supervised by healthcare workers—once they become aware of the risk—to avoid new variants with pandemic potential.
topic corona
pandemic
immunosuppression
emerging variants
risk
origin
url https://www.mdpi.com/1999-4915/13/5/751
work_keys_str_mv AT karinmoelling withinhostandbetweenhostevolutioninsarscov2newvariantssource
_version_ 1721509293835943936